1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNIH Common Fund - NIH Director's New Innovator Award is sponsored by National Institutes of Health (NIH). This award supports exceptionally creative new investigators who propose innovative, high-impact research projects.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NIH Director's New Innovator Award | NIH Common Fund NIH Director's New Innovator Award NIH Director's New Innovator Award FY2026 NIH Director’s New Innovator Award informational video Part of the High-Risk, High-Reward Research program, the NIH Director's New Innovator Award supports early career investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the NIH mission.
Part of the High-Risk, High-Reward Research program , the award supports early career investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the NIH mission.
Must have Early Stage Investigator status (completed doctoral degree or postgraduate clinical training within last 10 years and never received a substantial NIH independent research award) No preliminary data required Minimum of 25% research effort $475,000/year for 5 years See the Award Overview for more information. Applications due August 17, 2026.
Application & Award Guide Recent News & Announcements How Cellular Receptors Could Be Targeted to Treat Disease Nanoparticle Breakthrough Shows Potential for Treating Pre-Eclampsia Technological Improvements Propel Kidney Disease Research Forward New AI-Powered Device to Help Regain Motor Control This page last reviewed on
According to the current listing, eligibility includes: Typically targets new investigators who are exceptionally creative and propose innovative research. Specific eligibility criteria are detailed in each funding opportunity. Confirm the full requirements in the official notice before applying.
The current listing shows up to $475,000 direct costs per year for 5 years (about $2,375,000 direct). Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was August 17, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
NIH Common Fund - NIH Director's New Innovator Award is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article